SE513149C2 - Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna - Google Patents

Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna

Info

Publication number
SE513149C2
SE513149C2 SE9704549A SE9704549A SE513149C2 SE 513149 C2 SE513149 C2 SE 513149C2 SE 9704549 A SE9704549 A SE 9704549A SE 9704549 A SE9704549 A SE 9704549A SE 513149 C2 SE513149 C2 SE 513149C2
Authority
SE
Sweden
Prior art keywords
drug
distribution system
dna
targeting
drug distribution
Prior art date
Application number
SE9704549A
Other languages
English (en)
Swedish (sv)
Other versions
SE9704549L (sv
SE9704549D0 (sv
Inventor
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Original Assignee
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katarina Edwards, Joergen Carlsson, Stefan Sjoeberg filed Critical Katarina Edwards
Priority to SE9704549A priority Critical patent/SE513149C2/sv
Publication of SE9704549D0 publication Critical patent/SE9704549D0/xx
Priority to AT98962780T priority patent/ATE247949T1/de
Priority to US09/555,329 priority patent/US6562316B1/en
Priority to EP98962780A priority patent/EP1033972B1/de
Priority to DE69817602T priority patent/DE69817602T2/de
Priority to AU17938/99A priority patent/AU745059B2/en
Priority to PCT/SE1998/002231 priority patent/WO1999029302A1/en
Priority to JP2000523974A priority patent/JP2001525356A/ja
Priority to DK98962780T priority patent/DK1033972T3/da
Priority to CA002312767A priority patent/CA2312767C/en
Publication of SE9704549L publication Critical patent/SE9704549L/xx
Publication of SE513149C2 publication Critical patent/SE513149C2/sv

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9704549A 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna SE513149C2 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
CA002312767A CA2312767C (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
DE69817602T DE69817602T2 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting
US09/555,329 US6562316B1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
EP98962780A EP1033972B1 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting
AT98962780T ATE247949T1 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting
AU17938/99A AU745059B2 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
PCT/SE1998/002231 WO1999029302A1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting
JP2000523974A JP2001525356A (ja) 1997-12-05 1998-12-04 ２工程標的設定を用いた薬物送達システム
DK98962780T DK1033972T3 (da) 1997-12-05 1998-12-04 Medikamenttilførselssystem med totrinsmålretning

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna

Publications (3)

Publication Number Publication Date
SE9704549D0 SE9704549D0 (sv) 1997-12-05
SE9704549L SE9704549L (sv) 1999-06-06
SE513149C2 true SE513149C2 (sv) 2000-07-17

Family

ID=20409286

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna

Country Status (10)

Country Link
US (1) US6562316B1 (de)
EP (1) EP1033972B1 (de)
JP (1) JP2001525356A (de)
AT (1) ATE247949T1 (de)
AU (1) AU745059B2 (de)
CA (1) CA2312767C (de)
DE (1) DE69817602T2 (de)
DK (1) DK1033972T3 (de)
SE (1) SE513149C2 (de)
WO (1) WO1999029302A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2427146A1 (en) 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1877099B1 (de) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
WO2012112317A1 (en) * 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
ES2992024T3 (es) 2011-06-23 2024-12-05 Dsm Ip Assets Bv Nuevos copolímeros de poliesteramida biodegradables para la administración de fármacos
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
EP3368687B1 (de) * 2015-10-27 2021-09-29 The Broad Institute, Inc. Zusammensetzungen und verfahren gegen krebsspezifische sequenzvariationen
WO2021019575A1 (en) 2019-08-01 2021-02-04 Indian Institute Of Science A method for locomotion of a nanorobot and implementations thereof
CA3160955A1 (en) 2019-11-12 2021-05-20 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613937B1 (fr) * 1987-04-17 1989-07-21 Ire Celltarg Sa Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
US5328678A (en) * 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
EP0626943B1 (de) * 1991-10-31 2000-01-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Bistriazene als chemotherapeutische wirkstoffe
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
EP0723664A1 (de) * 1993-10-15 1996-07-31 Eva M. Rakowicz-Szulczynska Nachweiss und behandlung brustkrebsund gynäkologischer krebs
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US6180766B1 (en) * 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ，インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CZ299809B6 (cs) * 1996-05-08 2008-12-03 Nika Health Products Limited Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy
DE69727384T2 (de) * 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion

Also Published As

Publication number Publication date
CA2312767A1 (en) 1999-06-17
WO1999029302A1 (en) 1999-06-17
US6562316B1 (en) 2003-05-13
JP2001525356A (ja) 2001-12-11
SE9704549L (sv) 1999-06-06
AU1793899A (en) 1999-06-28
ATE247949T1 (de) 2003-09-15
EP1033972B1 (de) 2003-08-27
SE9704549D0 (sv) 1997-12-05
DE69817602T2 (de) 2004-06-24
CA2312767C (en) 2009-04-07
DK1033972T3 (da) 2003-12-22
EP1033972A1 (de) 2000-09-13
AU745059B2 (en) 2002-03-07
DE69817602D1 (de) 2003-10-02

Similar Documents

Publication Publication Date Title
SE513149C2 (sv) Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
Tian et al. Calcium bisphosphonate nanoparticles with chelator-free radiolabeling to deplete tumor-associated macrophages for enhanced cancer radioisotope therapy
Harrington et al. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies
Maruyama et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT)
ElBayoumi et al. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody
Soundararajan et al. [186Re] Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model
Guo et al. Receptor-specific delivery of liposomes via folate-PEG-chol
US7465716B2 (en) Targeted drug delivery with a hyaluronan ligand
US6897196B1 (en) pH sensitive lipids based on ortho ester linkers, composition and method
Riviere et al. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration
Qian et al. Minimizing adverse effects of Cerenkov radiation induced photodynamic therapy with transformable photosensitizer-loaded nanovesicles
Lila et al. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor
US20090081121A1 (en) Liposome compositions useful for tumor imaging and treatment
Chow et al. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging
US20220023450A1 (en) Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
Reilly et al. Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape
US20030170299A1 (en) Therapeutic methods for acute myeloid leukemia
Qiao et al. A robust approach to enhance tumor-selective accumulation of nanoparticles
Salerno et al. Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers
Zhao et al. Endogenous ROS-mediated covalent immobilization of gold nanoparticles in mitochondria: a “sharp sword” in tumor radiotherapy
Wang et al. Ultrasmall gold nanoparticles radiolabeled with iodine-125 as potential new radiopharmaceutical
Lingappa et al. Immunoliposomal delivery of 213Bi for α-emitter targeting of metastatic breast cancer
Dixit et al. Nano-radiopharmaceuticals as therapeutic agents
Zhi et al. Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer
Bao et al. Multimodal theranostic nanoparticles for necrosis targeting, fluorescence/SPECT imaging, and radiotherapy of residual tumors after hepatocellular carcinoma ablation

Legal Events

Date Code Title Description
NUG Patent has lapsed